News & Blog
Truvian featured in the WSJ: The Companies Realizing Theranos’s Failed Dream
Aspen Neuroscience: Study of ANPD001 Autologous Neuronal Cell Replacement Treatment Approach Published in Journal of Neurosurgery
Truvian Health raises $74M to bring blood testing to anyone, anywhere
SonoThera™ to Present Late Breakthrough Data at ISTH 2024 on Development of Nonviral Hemophilia A Gene Therapy Treatment
ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association
Aspen Neuroscience to Present at International Society for Cell & Gene Therapy (ISCT) Annual Meeting
Aspen Neuroscience Receives CLIN2 Grant for ANPD001 from California Institute for Regenerative Medicine (CIRM)
MEC in Q1 2024
AVILAR THERAPEUTICS TO PRESENT PRECLINICAL DATA FOR MTAC (M6PR TARGETING CHIMERA) EXTRACELLULAR PROTEIN DEGRADER PLATFORM AT THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS ANNUAL MEETING
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease